NF‐κB signaling in inflammation and cancer

  • Tao Zhang
    Cancer Center and Center for Immunology and Hematology West China Hospital Sichuan University Chengdu Sichuan China
  • Chao Ma
    Cancer Center and Center for Immunology and Hematology West China Hospital Sichuan University Chengdu Sichuan China
  • Zhiqiang Zhang
    Immunobiology and Transplant Science Center Houston Methodist Hospital Houston Texas USA
  • Huiyuan Zhang
    Cancer Center and Center for Immunology and Hematology West China Hospital Sichuan University Chengdu Sichuan China
  • Hongbo Hu
    Cancer Center and Center for Immunology and Hematology West China Hospital Sichuan University Chengdu Sichuan China

抄録

<jats:title>Abstract</jats:title><jats:p>Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered in 1986, extraordinary efforts have been made to understand the function and regulating mechanism of NF‐κB for 35 years, which lead to significant progress. Meanwhile, the molecular mechanisms regulating NF‐κB activation have also been illuminated, the cascades of signaling events leading to NF‐κB activity and key components of the NF‐κB pathway are also identified. It has been suggested NF‐κB plays an important role in human diseases, especially inflammation‐related diseases. These studies make the NF‐κB an attractive target for disease treatment. This review aims to summarize the knowledge of the family members of NF‐κB, as well as the basic mechanisms of NF‐κB signaling pathway activation. We will also review the effects of dysregulated NF‐κB on inflammation, tumorigenesis, and tumor microenvironment. The progression of the translational study and drug development targeting NF‐κB for inflammatory diseases and cancer treatment and the potential obstacles will be discussed. Further investigations on the precise functions of NF‐κB in the physiological and pathological settings and underlying mechanisms are in the urgent need to develop drugs targeting NF‐κB for inflammatory diseases and cancer treatment, with minimal side effects.</jats:p>

収録刊行物

  • MedComm

    MedComm 2 (4), 618-653, 2021-12

    Wiley

被引用文献 (2)*注記

もっと見る

問題の指摘

ページトップへ